Understanding Lung Squamous Cell Carcinoma Driven by PRKCI
A Genetically Tractable Mouse Model for PRKCI-driven Lung Squamous Cell Carcinoma
This research aims to better understand how certain genes contribute to lung squamous cell carcinoma, hoping to find new ways to treat this challenging cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Jacksonville NIH-funded |
| Lab location | 1 site (Jacksonville, United States) |
| Project ID | NIH-11120839 on NIH RePORTER |
What this research studies
Lung squamous cell carcinoma (LUSC) is a serious type of lung cancer that currently lacks effective targeted treatments, unlike other lung cancer types. This project focuses on specific genetic changes, like the loss of TP53 and gains in chromosome 3q26, which are common in LUSC and appear early in its development. Researchers believe that three genes in this region, PRKCI, SOX2, and ECT2, work together to drive LUSC growth. By studying how these genes interact and contribute to cancer in a controlled setting, we hope to uncover new targets for future therapies.
Who could benefit from this research
Good fit: This foundational research is for future patients with lung squamous cell carcinoma who may benefit from new targeted therapies.
Not a fit: Patients whose cancer is not driven by the specific genetic changes being studied, or those seeking immediate treatment options, may not directly benefit from this basic science work.
Why it matters
Potential benefit: If successful, this work could identify new targets for drug development, leading to more effective treatments for patients with lung squamous cell carcinoma.
How similar studies have performed: While new therapeutic strategies have improved outcomes for other lung cancer types, similar advances for lung squamous cell carcinoma have been limited due to a lack of well-understood targets, making this approach novel for LUSC.
Where this research is happening
Jacksonville, United States
- Mayo Clinic Jacksonville — Jacksonville, United States (Active)
Researchers
- Principal investigator: Fields, Alan P. — Mayo Clinic Jacksonville
- Study coordinator: Fields, Alan P.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.